The third quarter of 2026 has kicked off with 12 main merger and acquisition (M&A) offers and eight licensing agreements in world drug discovery and growth in July. Secure to say, curiosity in small molecules hasn’t waned, and cell and gene therapies and synthetic intelligence (AI) proceed to tug in investments.
Prime biotech M&As of July 2026
A number of multibillion-dollar acquisitions occurred in July. American biopharma Vertex Prescribed drugs’ first buyout this 12 months was of Crinetics Prescribed drugs. It purchased the California-based firm for $10 billion. Crinetics developed paltusotine, a small molecule for acromegaly, which was accredited by the U.S. Meals and Drug Administration (FDA) final 12 months. Acromegaly is a uncommon hormonal dysfunction attributable to extra progress hormone the place folks have enlarged tissues and organs.
Belgian firm Argenx has picked up autoimmune therapeutics firm Forte Biosciences for $2.2 billion. This provides Argenx management over the Texas primarily based startup’s monoclonal antibody FB102, which is present process scientific trials for celiac illness, vitiligo, and alopecia areata, all of which are attributable to an overactive immune system. Knowledge from the clinic are anticipated this 12 months. This broadens Argenx’s personal autoimmune therapies pipeline, with Vyvgart having been accredited in the U.S. and the European Union for myasthenia gravis.
Pharma big Lilly purchased New York-headquartered AtaiBeckley for $3.8 billion final month. AtaiBeckley is growing therapies for psychological well being situations like treatment-resistant melancholy and nervousness dysfunction. It’s lead candidate mebufotenin benzoate is in part 2 research and it works by binding to serotonin within the mind to reset neural circuits and elevate temper to deal with melancholy. Lilly has been on a roll these previous few months signing licensing and acquisition offers with biotechs in oncology, neurology, and infectious illness analysis.
In the meantime, Maryland-based biopharma NextCure has merged with Avere Therapeutics. The latter is growing a small molecule that inhibits the pro-inflammatory protein IL-23 to tackle inflammatory situations. This went hand-in-hand with the latter’s $320 million personal funding following a licensing take care of Chinese language firm Hansoh Pharma for as much as $2.3 billion. The monetary phrases of the merger weren’t disclosed.
Furthermore, Novartis is buying Myricx Bio, an antibody-drug conjugate (ADC) developer located in London, for as much as $1.5 billion. Novartis has expressed that this deal would strengthen its oncology pipeline. Myricx’s two ADCs goal B7-H3 and HER2 for strong tumors. That is following the Swiss big’s buy of allergy therapies developer Excellergy, introduced in March.
French firm Ipsen has plans to purchase Zurich-based Memo Therapeutics for €200 million ($228 million) upfront, with the chance for the latter to attain greater than €700 million ($798 million) in milestone funds. The Swiss firm is holding scientific trials for the antibody potravitug to deal with infections attributable to BK polyomavirus.
United Therapeutics has acquired Massachusetts-based stem cell firm Thymmune Therapeutics. Maryland-based United is paying $140 million in money to Thymmune and as much as $160 million in milestone funds by 2031. Thymmune’s lead candidate is a cell remedy for congenital athymia, an ultra-rare situation the place kids are born with no thymus – an organ that makes immune cells that assist struggle illness. The candidate is presently within the preclinical stage.
California-based Tarsus Prescribed drugs has shelled out $75 million to eye therapies firm iRenix Medical. The latter’s lead candidate is IRX-101, an antiseptic for the eyes. It’s designed to scale back post-procedural ache and corneal toxicity in sufferers who obtain intravitreal injections into their eyeballs. The antimicrobial is made from aqueous chlorine dioxide and in part 2b/3 research. Within the clinic, the remedy has helped lower ache and corneal fluorescein staining – a measure of corneal harm – in comparison with the antiseptic Betadine. As Tarsus takes over the reins, it might pay as much as $490 million in milestone funds.
British biotech Scancell and Massachusetts-based Neuphoria Therapeutics have merged and can now function underneath the identify Scancell. This comes after Neuphoria Therapeutics fended off a hostile takeover and proxy contest from activist investor Lynx1 Grasp Fund LP after a part 3 trial fail in treating social nervousness dysfunction with its lead small molecule soclenicant. Alternatively, Scancell’s focus is on oncology, with its lead antibody drug in part 2 trials for melanoma.
Australian firm Dimerix, specializing in inflammatory situations, has acquired Mission Therapeutics’ part 2-ready kidney illness asset. MTX652 is a USP30 inhibitor for acute kidney damage, a situation the place the kidneys all of a sudden can’t filter waste merchandise from the blood. The Cambridge-based biotech will rake in as much as $292 million in upfront and milestone funds. This provides Mission the monetary capability to develop its part 1 small molecule MTX325 for Parkinson’s illness.
American most cancers therapeutics startup Processa Prescribed drugs has purchased Vidya Therapeutics, which is growing a Bruton’s tyrosine kinase (BTK) inhibitor remedy for immune-mediated ailments. Vidya has applications in meals allergy, power spontaneous urticaria, and a number of sclerosis, all shifting to part 2 quickly. The monetary phrases of the deal weren’t disclosed.
Lastly, Massachusetts-based artificial biology firm Synlogic and Caldera Therapeutics have merged after Caldera was launched with $112.5 million in January. The brand new firm will go by Caldera Therapeutics. Its lead asset is a bispecific antibody for inflammatory bowel illness in part 1 research.
Biotech offers by method in July 2026
Small molecules in highlight
British huge pharma AstraZeneca inked two licensing offers within the small molecules sector final month. It has partnered with Chinese language firm Dizal Pharmaceutical to realize the worldwide rights to develop and commercialise Zegfrovy. The oral tyrosine kinase inhibitor was accredited by the FDA to deal with non-small cell lung most cancers (NSCLC) final 12 months and in China in 2023. The drug targets EGFR mutations. Now, AstraZeneca will market the medication. It should pay Dizal $600 million upfront and as much as $900 million in milestone funds.
Its second collaboration within the small molecules area is with Hong Kong-headquartered Sino Biopharmaceutical. The deal is over the PDE3/4 inhibitor, TQC3721, which AstraZeneca will develop and commercialize. Sino Biopharmaceutical will safe $200 million upfront and is eligible to earn as much as $1.9 billion in milestone funds.
Additional, Roche-owned Genentech has referred to as on Cambridge-headquartered Astex Prescribed drugs to determine small molecules for breast most cancers. As soon as the British pharmaceutical has picked out the potential candidates, Genentech can then take them by means of preclinical and scientific research. Astex will receive $25 million upfront and greater than $490 million in preclinical, scientific, regulatory, and gross sales milestones.
Licensing offers inked in CAR-T, RNAs, and AI
Massachusetts-based Sail Biomedicines, which develops in vivo CAR-T therapies, has united with pharma big Johnson & Johnson to advance cell therapies to handle immune-mediated ailments. Sail will seize $785 million and as much as $140 million in milestone funds. Sail’s eRNA and nanoparticle platform might be employed to create these new therapies. The pharma big has additionally secured the possibility to purchase Sail for an additional $2.58 billion. That is after the American big tapped Firefly Bio to develop degrader antibody conjugates for strong tumors again in June.
AstraZeneca’s third alliance in drug growth was with CSPC Pharmaceutical to co-develop small interfering RNA (siRNA) medication for kidney ailments from two undisclosed targets. The latter’s drug discovery platform and extrahepatic focused supply platform might be put to make use of, and AstraZeneca has procured the choices to license the preclinical candidates globally besides in China. AstraZeneca has been teaming up with biotechs positioned in China this 12 months, having signed one other pact with CSPC Pharmaceutical earlier this 12 months in weight reduction.
In the meantime, Massachusetts-based Spero Therapeutics is allying with Jiangsu-based Innovent Biologics to develop, analysis, manufacture, and commercialize the latter’s monoclonal antibody IBI355 globally excluding in China. Spero will take IBI355 to part 2 trials within the U.S., and Innovent will do the identical in China for Sjögren’s illness subsequent 12 months. Sjögren’s illness is an autoimmune dysfunction that assaults the glands that make tears and saliva. Innovent can collect as much as $1.1 billion in growth, regulatory, and business milestone funds, apart from an undisclosed upfront quantity.
German pharmaceutical Boehringer Ingelheim is becoming a member of forces with German biotech Prime Vector Applied sciences to convey most cancers vaccines to the market. The Tübingen-based startup’s Orf virus (ORFV) platform might be employed to design these vaccines. The monetary phrases of the deal weren’t revealed. Boehringer has been penning licensing offers in numerous therapeutics areas this 12 months, together with oncology, immunology, and metabolic illness.
Lastly, Japanese pharma big has knocked on Massachusetts-based Insilico Medication’s door to make use of the latter’s Pharma.AI platform to advance drug candidates throughout therapeutic areas. That is a part of Takeda’s transfer in direction of integrating automation, robotics, and AI in its drug discovery and growth course of. Insilico will shovel in $60 million in mission initiation charges, near-term funds, and milestones, as half of a complete of as much as $600 million in preclinical, scientific, business, and gross sales milestone funds.
